KSQ Therapeutics Stock

Drug discovery company

Sign up today and learn more about KSQ Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About KSQ Therapeutics Stock

KSQ Therapeutics states that it is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by a proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a more comprehensive understanding of disease biology. The quality of these insights enables their scientists to identify and validate high-confidence, patient-tailored drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Funding History

October 2017$76.0M
September 2018$80.0M



Frank Stegmeier


David Sabatini

VP, Head of Chemistry and Drug Design

René M. Lemieux

Sr. Director, Head of Corporate Development

John Trzupek

Managing Director & CEO

David Meeker

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: